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The cystine/glutamate exchanger (system xc − ) mediates the transport of cystine into the cell in exchange for glutamate. By releasing
glutamate, system xc − can potentially cause excitotoxicity. However, through providing cystine to the cell, it regulates the levels
of cellular glutathione (GSH), the main endogenous intracellular antioxidant, and may protect cells against oxidative stress. We
tested two different compounds that deplete primary cortical cultures containing both neurons and astrocytes of intracellular
GSH, L-buthionine-sulfoximine (L-BSO), and diethyl maleate (DEM). Both compounds caused significant concentration and time
dependent decreases in intracellular GSH levels. However; DEM caused an increase in radiolabeled cystine uptake through system
xc − , while unexpectedly BSO caused a decrease in uptake. The compounds caused similar low levels of neurotoxicity, while only
BSO caused an increase in oxidative stress. The mechanism of GSH depletion by these two compounds is different, DEM directly
conjugates to GSH, while BSO inhibits 𝛾-glutamylcysteine synthetase, a key enzyme in GSH synthesis. As would be expected from
these mechanisms of action, DEM caused a decrease in intracellular cysteine, while BSO increased cysteine levels. The results
suggest that negative feedback by intracellular cysteine is an important regulator of system xc − in this culture system.

1. Introduction
Under normal physiological conditions, the cystine/glutamate exchanger (system xc − ) mediates the transport of
cystine into the cell in exchange for releasing glutamate into
the extrasynaptic space. The exchange of extracellular cystine
and intracellular glutamate occurs in a one-to-one ratio. The
function of system xc − makes it likely to play an important
role in regulating neuronal survival and death. By releasing
glutamate, system xc − can increase extracellular glutamate
levels and potentially cause excitotoxicity. Release of glutamate via system xc − , from both microglia and astrocytes,
has been shown to enhance excitotoxicity of cortical neurons
[1–4]. However, through providing cystine to the cell, it
regulates the levels of intracellular glutathione (GSH), the
main endogenous intracellular antioxidant, and in this way
may protect cells against oxidative stress [5, 6].
Not only does system xc − act to prevent oxidative stress,
but it also appears that such stress is an important trigger for
its upregulation. Direct induction of oxidative stress has been
shown to upregulate system xc − function in a retinal ganglion

cell line [7] and in retinal Muller glial cells [8]. Compounds
that deplete cellular GSH levels upregulate system xc − function in a glioma cell line [9] and in primary astrocytes [10],
although there is not always a correlation between depletion
of GSH and upregulation of system xc − [11].
The first step in the production of GSH in the brain is
believed to involve uptake of cystine, primarily into astrocytes
[12]. Most of the cystine transported into cortical astrocytes
appears to be through system xc − [13]. Once in the astrocytes
cystine is immediately broken down by thioredoxin reductase
1 into two cysteine molecules [14]. GSH is synthesized via
a two-step reaction [15, 16]. First, glutamate and cysteine
are catalyzed to 𝛾-glutamylcysteine by 𝛾-glutamylcysteine
synthetase. Then glutathione synthetase combines glycine
with 𝛾-glutamylcysteine forming GSH. Both glutamate and
glycine are highly available in the cells, so the rate-limiting
factor in the production of GSH is the levels of cysteine
present in the cell [17].
Glutathione can be utilized by cells to reduce reactive oxygen species; for example, superoxide produced as
a byproduct of mitochondrial energy production rapidly

2
reacts to form hydrogen peroxide which is then reduced
by GSH to form glutathione disulfide (GSSG) and water in
a reaction catalyzed by glutathione peroxidase. Glutathione
may also be utilized as a xenobiotic detoxicant as has been
well characterized involving chemotherapeutics in cancer
treatment [18]. That is, GSH can be directly conjugated
to exogenous substrates via a disulfide bond with the free
sulfhydryl groups; these reactions are directed by a class
of enzymes known as glutathione-S-transferases (GSTs) [17,
19]. GSH, GSSG, and the glutathione conjugates are then
exported from the cell in a glutathione-dependent manner
via multidrug resistance proteins (MRP), specifically MRP1 in
the CNS [20, 21]. GSH molecules produced by astrocytes can
then be broken down in the extracellular space by glutathione
reductase, aminopeptidase N, or 𝛾-glutamyl transpeptidase.
This metabolism produces the substrate cysteine, which
can be taken up and utilized by neurons to produce their
own GSH [22–24]. In this way, neurons are dependent on
astrocytes to supply the substrate for their GSH production
[25]. The importance of cysteine uptake into neurons is
indicated by the finding that knocking out the excitatory
amino acid transporter-3 (EAAT3) greatly reduces neuronal
cysteine uptake and intracellular GSH levels, resulting in
decreased viability of hippocampal neurons against hydrogen
peroxide insults [26–28].
The current studies used mixed cultures of neurons and
astrocytes to be able to incorporate the important interaction
between these cell types. The studies involve assessing the
effects of two different approaches to deplete cellular GSH.
Diethyl maleate (DEM) directly conjugates to GSH while
buthionine sulfoximine (BSO) inhibits 𝛾-glutamylcysteine
synthetase preventing the production of GSH. The studies
were designed to determine the effects of these different
mechanisms of GSH depletion on system xc − function.

2. Materials and Methods
2.1. Materials. Timed pregnant Swiss Webster mice were
obtained from Charles River Laboratories (Wilmington, DE,
USA). Serum was from Atlanta Biologicals (Atlanta, GA,
USA). NADPH was from Applichem (Darmstadt, Germany).
Radiolabeled 14 C-cystine was purchased from PerkinElmer
(Boston, MA, USA). DCF was from Molecular Probes
(Eugene, OR, USA). All other chemicals were from SigmaAldrich (St. Louis, MO, USA).
2.2. Cortical Cell Cultures. Mixed cortical cell cultures containing glial and neuronal cells were prepared from fetal
(15-16 day gestation) mice as previously described [29].
Dissociated cortical cells were plated on 24-well plates
(2.0 cm2 surface area per well) coated with poly-D-lysine and
laminin in Eagles’ minimal essential medium (MEM, Earle’s
salts, supplied glutamine-free) supplemented with 5% (v/v)
heat-inactivated horse serum, 5% (v/v) fetal bovine serum,
2 mM glutamine, and D-glucose (total 21 mM). Cultures were
maintained in humidified 5% CO2 incubators at 37∘ C with
experiments performed on cultures DIV 13–15. Mice were
handled in accordance with a protocol approved by our

Oxidative Medicine and Cellular Longevity
institutional animal care committee and in compliance with
the Public Health Service Policy on Humane Care and Use
of Laboratory Animals. All efforts were made to minimize
animal suffering and reduce the number of animals used.
Experiments were performed in media lacking serum (MS),
but otherwise identical to the growth media.
2.3. Assay of Neuronal Death. Cell death was assessed in cultures by the measurement of lactate dehydrogenase (LDH),
released from damaged or destroyed cells, in the extracellular
fluid 24 hours after the beginning of the insult. Control
LDH levels were subtracted from insult LDH values, and
results normalized to 100% neuronal death caused by 500 𝜇M
NMDA. Control experiments have shown previously that the
efflux of LDH occurring from either necrotic or apoptotic
cells is proportional to the number of cells damaged or
destroyed [29, 30]. Cultures were also examined visually
following trypan blue staining.
2.4. 2 ,7 -Dichlorofluorescein (DCF) Assay of Oxidative Stress.
Oxidative stress was assayed by measuring DCF oxidation
using a fluorescent plate reader following a modification
of a previous method [31, 32]. Cultures were exposed to
100 𝜇M DEM or BSO for the indicated period of time
after which they were exposed to 5-(and-6)-carboxy-2 ,7 dichlorodihydrofluorescein diacetate (carboxy-H2 DCFDA)
(10 𝜇M). The carboxy-H2 DCFDA is de-esterfied within cells
to form a free acid that can then be oxidized to the fluorescent
2 ,7 -dichlorofluorescein (DCF). After a 30-minute exposure
to carboxy-H2 DCFDA, cultures were washed 3 times with
culture media lacking serum. Fluorescence was then measured using a Fluoroskan Ascent fluorescence plate reader
(Thermo Labsystems). The excitation filter was set at 485 nm
and emission filter at 538 nm. Background fluorescence (no
carboxy-H2 DCFDA added) was subtracted and the results
normalized to control conditions (carboxy-H2 DCFDA added
but no DEM or BSO).
2.5. Monochlorobimane (MCB) Assay of Cellular Reduced
GSH. Cellular GSH levels were measured by MCB fluorescence. MCB forms a fluorescent compound when it reacts
with GSH through a reaction catalyzed by glutathione-Stransferase [33]. Cultures were exposed to the indicated
concentrations of DEM or BSO for the indicated period
of time after which they were exposed to MCB (10 𝜇M).
After 30 minutes, the cultures were excited at a wavelength
of 355 nm and emission was measured at a wavelength of
460 nm using a Thermo Labsystems Fluoroskan microplate
reader. Background (no MCB added) was subtracted and the
results normalized to control (MCB added but no DEM or
BSO).
2.6. HPLC Analysis of Cellular Cysteine Levels. To assess cysteine concentrations, cultures were exposed to MS containing
the indicated drug for 6 or 24 hours. After the indicated time,
cultures were washed with balanced salt solution (BSS) and
then scraped into 250 𝜇L HPLC mobile phase. Cells were
collected into microcentrifuge tubes, sonicated using a probe
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sonicator and analyzed for protein content using the common
BCA method. Once the protein content was determined,
the homogenized samples were spun through a centrifugal
filter and the resulting protein-free sample was injected onto
a Shimadzu HPLC system coupled with an electrochemical
detector. Separation was obtained with a reverse phase C-18
column and an ion-pairing mobile phase (50 mM citric acid,
10 mM octane sulfonic acid, pH 2.80, and 1% acetonitrile).
Resulting cysteine concentrations were normalized by the
protein content and values are reported as percent control.
2.7. 14 C-Cystine Uptake. Radiolabeled cystine uptake was
performed as previously described with modifications [34].
Cultures were exposed to MS containing the indicated drug
treatments for 40 min, 6 hrs, or 24 hrs. After the drug exposure, cultures were washed into HEPES buffered saline solution and immediately exposed to 14 C-cystine (0.025 𝜇Ci/mL,
200 nM total cystine) for 20 minutes. Following 14 C-cystine
exposure, cultures were washed with ice cold HEPES buffered
saline solution and dissolved in 250 𝜇L warm sodium dodecyl
sulfate (0.1%). An aliquot (200 𝜇L) was removed and added
to scintillation fluid for counting. Values were normalized to
control.
2.8. Statistical Analysis. Differences between test groups were
examined for statistical significance by means of one-way
ANOVA followed by the Bonferroni post hoc analysis, with
𝑃 < 0.05 being considered significant.

3. Results
We set out to determine whether depleting cellular GSH
alters system xc − activity as assessed by measuring 14 Ccystine uptake in mixed cortical cell cultures. We have shown
previously that the large majority of 14 C-cystine uptake in
mixed cortical cultures is mediated by system xc − uptake into
astrocytes [13]. In the current studies, cellular GSH levels were
depleted using two compounds with different mechanisms of
action. DEM directly conjugates to GSH, while BSO inhibits
GSH synthesis. Varying concentrations of DEM were added
to mixed cortical cultures for 40 min, 6 hr, or 24 hrs, with 14 Ccystine uptake measured for 20 minutes following the exposure. DEM caused a significant increase in 14 C-cystine uptake
at all time points at a concentration of 100 𝜇M, and at 40 min
and 24 hrs at the 10 𝜇M concentration (Figure 1). In contrast
to DEM, when cultures were exposed to BSO at the same
concentrations, BSO did not cause an increase in 14 C-cystine
uptake at any concentration or time point. In fact, BSO at a
concentration of 100 𝜇M caused a significant decrease in 14 Ccystine uptake after 6 hr treatment, while both 10 and 100 𝜇M
BSO caused a decrease at 24 hrs (Figure 1).
To test whether the increased uptake induced by DEM
treatment was mediated by system xc − , the inhibitor of that
system, sulfasalazine (SSZ), was added during the uptake
period following exposure to 100 𝜇M DEM. The SSZ treatment completely blocked the increased 14 C-cystine uptake
induced by DEM (Figure 2).

3
A potential cause for altered 14 C-cystine uptake could
be toxicity of DEM or BSO. DEM and BSO both caused a
small, but significant, level of neurotoxicity after 24 hours at
the 100 𝜇M concentrations (Figure 3). Trypan blue staining
indicated that the death was selective for neurons (data not
shown).
A potential mechanism by which DEM may have caused
increased system xc − activity is through inducing oxidative
stress which has been shown to upregulate system xc − [7, 8].
We measured cellular oxidative stress with the compound
DCF, which becomes fluorescent when oxidized. Somewhat
surprisingly we did not see enhanced DCF fluorescence
following 100 𝜇M DEM treatment, while 100 𝜇M BSO only
caused an increase following 24 hr treatment (Figure 4).
Another potential mechanism by which DEM may be
causing increased system xc − function is through causing
decreased GSH levels. DEM and BSO treatment both caused
a decrease in cellular GSH levels (Figure 5). There were some
differences in the decrease, and DEM caused a more rapid
decrease in GSH, with a significant decrease at the 40-minute
time point, while BSO did not cause a significant decrease
until the 6 hr time point. The GSH levels with DEM treatment
actually increased from the 6 hr time point to the 24 hr time
point, so that, at 24 hrs, BSO caused a greater decrease in GSH
levels compared to DEM.
While DEM and BSO both act to decrease GSH levels,
they do so by different mechanisms suggesting the possibility
that they may alter cellular cysteine levels differently. We
found that 100 𝜇M DEM caused a significant decrease in
cellular cysteine levels after 6 hr treatment with the effect
disappearing at 24 hours, while 100 𝜇M BSO caused a significant increase in cellular cysteine after 6 and 24 hr treatment
(Figure 6).

4. Discussion
The regulation of system xc − function is proving to be complicated, likely because of its varied functions. Upregulation
of system xc − by oxidative stress has been well established and
this regulation is mechanistically understandable considering
that system xc − is important for cystine uptake and therefore
GSH production. However, system xc − function has also been
shown to be upregulated by a diverse array of compounds
including IL-1𝛽 [2], erythropoietin [35], FGF-2 [36], IGF1 [33, 37], TGF-𝛽 [33], and PACAP [38]. While system xc −
function has been shown to be decreased by dexamethasone
[39], regulation by these diverse compounds may reflect
the importance of system xc − in regulating not only oxidative stress but also extracellular glutamate. For example, it
has been shown that cocaine addiction is associated with
impaired system xc − function leading to decreased activation
of presynaptic group II mGluRs leading to increased synaptic
release of glutamate [40, 41]. It is likely that the regulation
of system xc − by these compounds reflects the importance
of regulating both intracellular GSH and extracellular glutamate. Another factor to consider is that there is an interaction
between system xc − and excitatory amino acid transporters
(EAATs) [42]. The possibility that altered EAAT function
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Figure 1: Diethyl maleate (DEM) exposure causes an increase, while buthionine sulfoximine (BSO) exposure causes a decrease, in 14 C-cystine
uptake in mixed cortical cultures. Cultures were exposed to varying concentrations of DEM or BSO for (a) 40 min, (b) 6 hrs, or (c) 24 hrs,
after thorough washing, 14 C-cystine uptake was measured for 20 minutes. Results are expressed as mean + SEM (𝑛 = 8–16) after normalizing
to untreated control uptake. ∗ indicates significant difference from control; 𝑃 < 0.05.

could change glutamate concentrations and in this way
change system xc − function exists.
The goal of the current study was to examine in more
detail the regulation of system xc − by agents that deplete
GSH. The previous thinking about such agents is that they
upregulated system xc − by depletion of cellular GSH, and
either this depletion directly stimulated system xc − or the
resulting increased oxidative stress caused the upregulation.
Our results indicate another potential mechanism of regulation. In our studies, simple depletion of cellular GSH did
not appear to be the trigger for upregulation of system xc − .
While there were some differences in the time course and
concentration dependence of the effects of DEM and BSO
treatment on GSH levels, they both caused depletion of GSH
and yet they had opposite effects on system xc − function.

These results are difficult to explain by the different time
courses in effects on GSH levels. If BSO caused no effect on
system xc − function this could potentially be explained by its
slower depletion of GSH, but the fact that it actually caused a
decrease in system xc − activity seems unlikely to be explained
by the slower loss of GSH with BSO treatment compared to
with DEM treatment. Interestingly, the GSH levels following
DEM treatment actually increased from the 6 hr time point to
the 24 hr time point (Figure 5). This increase is likely due to
the upregulation of system xc − under these conditions leading
to increased cystine uptake and additional substrate for GSH
production.
Toxicity due to treatment with DEM or BSO could be a
potential confound when assessing cystine uptake. However,
both compounds caused only a small degree of neurotoxicity
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Figure 2: DEM induced increase in 14 C-cystine uptake is mediated
by system xc − . Cultures were exposed to 100 𝜇M DEM for 40 min,
6 hrs, or 24 hrs, after thorough washing, 14 C-cystine uptake was
measured for 20 minutes with or without the system xc − inhibitor
sulfasalazine (SSZ) present. Results are expressed as mean + SEM (𝑛
= 8–16) after normalizing to untreated control uptake. ∗ indicates
significant difference from control; 𝑃 < 0.05.
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Figure 3: DEM and BSO cause similar low levels of neurotoxicity.
Concentration response curve for 24 hr exposure to DEM and BSO
on LDH release in primary cortical cultures. Results are expressed
as mean + SEM (𝑛 = 8–16). ∗ indicates significant difference from
untreated control; 𝑃 < 0.05.

(10–15%) after 24 hours. This toxicity seems unlikely to play
a major role in the results for three reasons. First, DEM
and BSO caused similar toxicity but had opposite effects on
cystine uptake. Second, the levels of cell death were small
compared to the magnitude of changes in cystine uptake.
Third, the cell death was selective for neurons, while most of
the cystine uptake in this culture system is into astrocytes [13].
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Figure 4: BSO, but not DEM, causes an increase in cellular oxidative
stress as measured by DCF fluorescence after 24 hour treatment.
Bars show % DCF fluorescence normalized to control fluorescence
(mean + SEM, 𝑛 = 8–16). ∗ indicates significant difference from
control. 𝑃 < 0.05.

The result that DEM did not induce oxidative stress,
as measured by DCF fluorescence, suggests that increased
oxidative stress is not the mechanism by which DEM
upregulates system xc − function, particularly since BSO did
induce oxidative stress while it actually decreased system xc −
function. However, it was somewhat surprising that DEM did
not induce oxidative stress since it did decrease the levels
of GSH. There are a number of possible explanations for
this result. First, GSH is not the only antioxidant present
in the brain. Under the conditions we were studying it
is possible that decreased GSH levels would not lead to
enhanced oxidative stress in the cells. Second, the DCF assay
does not detect all forms of free radicals [43] and it may be less
effective in detecting mitochondria selective oxidative stress
[44]. Therefore, while we cannot absolutely conclude that
oxidative stress is not the trigger for upregulation of system
xc − by DEM, the fact that BSO caused a marked increase
in oxidative stress while DEM did not, and yet BSO caused
a decrease in system xc − function, suggesting that factors
other than oxidative stress are more important in regulation
of system xc − in this system.
Our results suggest that, at least for our cell culture
system, cysteine is a more important regulator of system xc −
function than GSH. DEM caused both a decrease in cysteine
and GSH levels, consistent with its action to conjugate
GSH leading to constant use of cellular cysteine. Therefore,
either the decrease in cysteine or GSH could be responsible
for the upregulation of system xc − . However, BSO also
decreased GSH but increased cysteine levels, consistent with
its action to inhibit 𝛾-glutamylcysteine synthetase leading
to GSH depletion but buildup of cysteine, and it caused
a downregulation of system xc − function. In this case, the
most likely explanation for the effect is that the buildup of
cysteine provides negative feedback on system xc − function.
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Figure 5: DEM and BSO cause a concentration dependent decrease in cellular glutathione levels. Cultures were exposed to varying
concentrations of DEM or BSO for (a) 40 min, (b) 6 hrs, or (c) 24 hrs, after which cellular reduced glutathione was determined by MCB
fluorescence. Bars show % MCB fluorescence normalized to control fluorescence (mean + SEM, 𝑛 = 8–16). ∗ indicates significant difference
from control. 𝑃 < 0.05.

This type of regulation makes sense physiologically. The levels
of cysteine in the cell are more directly related to the uptake
of cystine than they are to the levels of GSH. Glutathione
levels in cells could be altered by changes in the function
of 𝛾-glutamylcysteine synthetase or glutathione synthetase or
potentially the availability of glycine or glutamate. Therefore,
if system xc − was upregulated by GSH depletion, it could be in
response to conditions unrelated to the availability of cystine.
Additionally, cysteine levels in the brain are 100 times lower
than GSH levels [45] and, therefore, rapid changes in their
levels are more likely to occur than changes in GSH levels.
Our results are in contrast to those of Seib [10], who
found a large increase in system xc − function in astrocytes
after treatment with BSO. There are two major differences
in the culture systems used for the studies. First, we used
a mixed neuronal and astrocyte culture, while in the Seib

study they used a pure astrocyte culture. The possibility exists
that the interaction of neurons with the astrocytes alters the
how-cells-regulate system xc − . Second, their cultures received
long-term treatment with a cell permeant form of cAMP
prior to the BSO treatment. From their studies, it is clear that
GSH levels can also be an important regulator of system xc − ,
but that the status of the cells likely determines the relative
importance of cysteine or GSH in the regulation. We cannot
exclude the possibility that GSH plays a role in regulating
system xc − even in our culture conditions, but it appears that
cysteine levels have a greater effect than GSH on system xc −
function. The implications this finding has for the role of
system xc − in disease conditions are not certain. Cysteine
levels are not as commonly measured as GSH levels. For
example, we have found that system xc − function is increased
at 70 days of age in the G93A-SOD1 mouse model of ALS [46],
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Figure 6: DEM causes an early decrease in cellular cysteine levels, while BSO causes an early and late increase in cellular cysteine levels.
Cultures were exposed to varying concentrations of DEM or BSO for (a) 6 hrs or (b) 24 hrs, after which cellular cysteine levels were determined
by HPLC. Bars show % cellular cysteine normalized to control (mean + SEM, 𝑛 = 8). ∗ indicates significant difference from control 𝑃 < 0.05.

a time point at which GSH levels are not yet decreased [47],
but intracellular cysteine levels are unknown.
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5. Conclusions
Our studies indicate that, at least under some conditions,
intracellular levels of cysteine are a more important regulator
of system xc − than intracellular levels of GSH. We did not
determine the mechanism of regulation by cysteine, but the
redox sensitive transcription factor Nrf2 has been shown to
be the main regulator of system xc − [11, 48]. This finding
puts system xc − in the context of it being one factor in the
role of Nrf2 as the master regulator of the cellular response
to oxidative stress [49]. In conclusion, studies involving
assessment of levels of cysteine, GSH, and system xc − function
during disease conditions will be required to determine the
most important regulator of system xc − function in disease
states.
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